Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3035934

CC(C)(C1CCN(C(=O)[C@@H](N)C2CCCCC2)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.54
CYP3A4 P08684 2/20 0.54
NR1I2 O75469 2/20 0.54
CNR1 P21554 1/20 0.45
DPP4 P27487 7/20 0.41
DPP7 Q9UHL4 7/20 0.41
KCNH2 Q12809 2/20 0.41
SMYD3 Q9H7B4 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PREP P48147 1/20 0.40
F2 P00734 1/20 0.40
DPP8 Q6V1X1 2/20 0.40
DPP9 Q86TI2 2/20 0.40
POLB P06746 1/20 0.40
EPHX1 P07099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14701495 0.96 CACNA1B (0.57) CACNA1BCYP3A4NR1I2CNR1DPP4
SCHEMBL13221486 0.96 CACNA1B (0.57) CACNA1BCYP3A4NR1I2CNR1DPP4
Trifluoroacetic Acid SCHEMBL3035820 0.85 CACNA1B (0.55) CACNA1BCYP3A4NR1I2CNR1DPP4
Trifluoroacetic Acid SCHEMBL3040279 0.85 CACNA1B (0.55) CACNA1BCYP3A4NR1I2DPP4DPP7
Trifluoroacetic Acid SCHEMBL3032282 0.85 CACNA1B (0.55) CACNA1BCYP3A4NR1I2CNR1DPP4
Trifluoroacetic Acid SCHEMBL3032929 0.84 CACNA1B (0.54) CACNA1BCYP3A4NR1I2DPP4DPP7
Trifluoroacetic Acid SCHEMBL3032237 0.84 CACNA1B (0.54) CACNA1BCYP3A4NR1I2DPP4DPP7
SCHEMBL3256020 0.84 CACNA1B (0.61) CACNA1BCYP3A4NR1I2CNR1SMYD3
SCHEMBL13221500 0.82 CACNA1B (0.58) CACNA1BCYP3A4NR1I2CNR1SMYD3
SCHEMBL15103504 0.82 CACNA1B (0.58) CACNA1BCYP3A4NR1I2CNR1SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP claimed
US-8304434-B2 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME CORP. (US) 2012-11-06 US claimed
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers SCHERING CORPORATION 2010-08-19 US claimed
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2013-02-14 US disclosed
US-8304434-B2 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME CORP. (US) 2012-11-06 US disclosed
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers SCHERING CORPORATION 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.